MUSTANG BIO, INC. Contracts & Agreements
80 Contracts & Agreements
- Business Finance (41 contracts)
- Business Operations (9)
- Human Resources (4)
- Intellectual Property (6)
- Real Estate (5)
- Uncategorized (15)
- Form of Indemnification Agreement (Filed With SEC on October 25, 2024)
- Form of Investor Inducement Letter (Filed With SEC on October 25, 2024)
- Form of Placement Agent Warrant (Filed With SEC on October 25, 2024)
- Form of New Series B-2 Warrant (Filed With SEC on October 25, 2024)
- Form of New Series B-1 Warrant (Filed With SEC on October 25, 2024)
- Asset Purchase Agreement, dated June 27, 2024, between the Company and uBriGene (Boston) Biosciences, Inc (Filed With SEC on July 3, 2024)
- Form of Warrant (Filed With SEC on June 24, 2024)
- Form of Pre-funded Warrant (Filed With SEC on June 24, 2024)
- Form of Wainwright Warrant (Filed With SEC on June 24, 2024)
- Form of Securities Purchase Agreement, dated June 19, 2024, by and between the Company and the purchaser party thereto (Filed With SEC on June 24, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on May 2, 2024)
- Form of Series A-1, A-2, and A-3 Warrant (Filed With SEC on May 2, 2024)
- Form of Placement Agent Warrant (Filed With SEC on May 2, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on May 2, 2024)
- Warrant Agreement Amendment (Filed With SEC on May 2, 2024)
- Form of Series A-1, Series A-2, and Series A-3 Warrant offered hereby (Filed With SEC on April 29, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on April 29, 2024)
- Form of Pre-Funded Warrant offered hereby (Filed With SEC on April 2, 2024)
- Form of Warrant offered hereby (Filed With SEC on April 2, 2024)
- Form of Placement Agent Warrant (Filed With SEC on April 2, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on April 2, 2024)
- Form of Director Stock Award Agreement (Filed With SEC on March 11, 2024)
- Form of Restricted Stock Unit Agreement (Filed With SEC on March 11, 2024)
- Form of Option Agreement (Filed With SEC on March 11, 2024)
- Description of Securities of Mustang Bio, Inc (Filed With SEC on March 11, 2024)
- Form of Securities Purchase Agreement, dated October 26, 2023, by and between the Company and the purchaser party thereto (Filed With SEC on October 30, 2023)
- Form of Wainwright Warrant (Filed With SEC on October 30, 2023)
- Form of Warrant (Filed With SEC on October 30, 2023)
- Form of Pre-funded Warrant (Filed With SEC on October 30, 2023)
- Sub-Contracting Manufacturing Services Agreement, dated July 28, 2023, between the Company and uBriGene (Boston) Biosciences, Inc (Filed With SEC on July 31, 2023)
- Manufacturing Services Agreement, dated July 28, 2023, between the Company and uBriGene (Boston) Biosciences, Inc (Filed With SEC on July 31, 2023)
- Second Amendment to Asset Purchase Agreement, dated July 28, 2023, between the Company and uBriGene (Boston) Biosciences, Inc (Filed With SEC on July 31, 2023)
- Third Amendment to Sublease, dated June 15, 2023, between the Company and The Paul Revere Life Insurance Company (Filed With SEC on July 20, 2023)
- Second Amendment to Sublease, dated April 27, 2023, between the Company and The Paul Revere Life Insurance Company (Filed With SEC on July 20, 2023)
- First Amendment to Asset Purchase Agreement, dated June 29, 2023, between the Company and uBriGene (Boston) Biosciences, Inc (Filed With SEC on June 30, 2023)
- Amendment No. 2 to the Mustang Bio, Inc. 2019 Employee Stock Purchase Plan (Filed With SEC on June 23, 2023)
- Asset Purchase Agreement, dated May 18, 2023, between the Company and uBriGene (Boston) Biosciences, Inc (Filed With SEC on May 22, 2023)
- Amendment No. 3 to At Market Issuance Sales Agreement, dated April 14, 2023, between the Company, B. Riley Securities, Inc., Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (Filed With SEC on April 20, 2023)
- First Amendment to Sublease Agreement by and between Mustang Bio, Inc. and The Paul Revere Life Insurance Company, dated October 25, 2022 (Filed With SEC on March 30, 2023)
- Sublease Agreement by and between Mustang Bio, Inc., and The Paul Reverse Life Insurance Company, dated June 14, 2022 (Filed With SEC on March 30, 2023)
- Description of Securities of Mustang Bio, Inc (Filed With SEC on March 30, 2023)
- First Amendment to Loan and Security Agreement, dated December 7, 2022, by and between Mustang Bio, Inc., the Borrower, the Lenders and the Agent (Filed With SEC on December 13, 2022)
- Third Amendment to Mustang Bio, Inc. 2016 Incentive Plan (Filed With SEC on June 24, 2022)
- Description of Securities of Mustang Bio, Inc (Filed With SEC on March 23, 2022)
- Warrant to Purchase Common Stock issued March 4, 2022, by Mustang Bio, Inc. to Runway Growth Finance Corp (Filed With SEC on March 8, 2022)
- Amended and Restated Exclusive License Agreement dated August 13, 2021 by and between Mustang Bio, Inc. and City of Hope (CS1) (Filed With SEC on August 16, 2021)
- Amended and Restated Exclusive License Agreement dated August 13, 2021 by and between Mustang Bio, Inc. and City of Hope (HER2) (Filed With SEC on August 16, 2021)
- Amended and Restated Exclusive License Agreement dated August 13, 2021 by and between Mustang Bio, Inc. and City of Hope (PSCA) (Filed With SEC on August 16, 2021)
- Amendment to Mustang Bio, Inc. 2019 Employee Stock Purchase Plan (Filed With SEC on June 22, 2021)
- Second Amendment to Mustang Bio, Inc. 2016 Incentive Plan (Filed With SEC on June 22, 2021)
- Description of Securities of Mustang Bio, Inc (Filed With SEC on March 24, 2021)
- Amendment No. 2 to At Market Issuance Sales Agreement, dated December 31, 2020, between the Company, B. Riley Securities, Inc., Cantor Fitzgerald & Co., National Securities... (Filed With SEC on December 31, 2020)
- Amendment No. 1 to At Market Issuance Sales Agreement, dated July 20, 2020, between the Company, B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation and... (Filed With SEC on July 24, 2020)
- At Market Issuance Sales Agreement, dated July 27, 2018, between the Company, B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation and Oppenheimer & Co. Inc (Filed With SEC on July 24, 2020)
- Underwriting Agreement, dated June 11, 2020 by and between Mustang Bio, Inc. and Cantor Fitzgerald & Co., as representative of the underwriters named therein (Filed With SEC on June 15, 2020)
- Description of Securities of Mustang Bio, Inc (Filed With SEC on March 16, 2020)
- 2019 Employee Stock Purchase Plan (Filed With SEC on August 9, 2019)
- Underwriting Agreement, dated April 30, 2019 by and between Mustang Bio, Inc. and Cantor Fitzgerald & Co., as representative of the several underwriters named therein (Filed With SEC on April 30, 2019)
- Warrant to Purchase Common Stock (Loan B) issued March 29, 2019 by the Company to Horizon Technology Finance Corporation (Filed With SEC on April 4, 2019)
- Warrant to Purchase Common Stock (Loan A) issued March 29, 2019 by the Company to Horizon Technology Finance Corporation (Filed With SEC on April 4, 2019)
- Warrant to Purchase Common Stock (Loan C) issued March 29, 2019 by the Company to Horizon Technology Finance Corporation (Filed With SEC on April 4, 2019)
- Warrant to Purchase Common Stock (Loan D) issued March 29, 2019 by the Company to Horizon Technology Finance Corporation (Filed With SEC on April 4, 2019)
- Venture Loan and Security Agreement, dated March 29, 2019, by and between the Company and Horizon Technology Finance Corporation (Filed With SEC on April 4, 2019)
- Executive Employment Agreement, by and between Mustang Bio, Inc. and Martina A. Sersch, M.D., Ph.D., entered into as of October 4, 2018 (Filed With SEC on November 13, 2018)
- At Market Issuance Sales Agreement, dated July 27, 2018, between the Company, B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation, and Oppenheimer & Co.... (Filed With SEC on July 27, 2018)
- Lease Agreement, by and between the Company and WCS - 377 Plantation Street, Inc., dated October 27, 2017 (Filed With SEC on November 14, 2017)
- EXCLUSIVELICENSE AGREEMENT (Filed With SEC on August 14, 2017)
- EXCLUSIVELICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND MUSTANG BIO, INC. FOR UCLA CaseNo. *: “Engineered Anti-Prostate Stem Cell Antigen (PSCA)... (Filed With SEC on August 14, 2017)
- EXCLUSIVELICENSE AGREEMENT (Filed With SEC on August 14, 2017)
- EXCLUSIVELICENSE AGREEMENT (Filed With SEC on August 14, 2017)
- EXCLUSIVELICENSE AGREEMENT (Filed With SEC on August 14, 2017)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on April 24, 2017)
- EXCLUSIVELICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND MUSTANG BIO, INC. FOR UCLA Case No.*: “Engineered Anti-Prostate Stem Cell Antigen (PSCA)... (Filed With SEC on March 31, 2017)
- BOARD ADVISORY SERVICES AGREEMENT (Filed With SEC on March 31, 2017)
- EXCLUSIVELICENSE AGREEMENT (Filed With SEC on March 31, 2017)
- AMENDED ANDRESTATED EXCLUSIVE LICENSE AGREEMENT – CD123 (Filed With SEC on March 31, 2017)
- AMENDED ANDRESTATED EXCLUSIVE LICENSE AGREEMENT – IL-13 (Filed With SEC on March 31, 2017)
- AMENDEDAND RESTATED EXCLUSIVE LICENSE AGREEMENT – Spacer (Filed With SEC on March 31, 2017)
- PLACEMENT AGENT AGREEMENT Dated: August 3, 2016 (Filed With SEC on November 14, 2016)
- UNIT PURCHASE AGREEMENT (Filed With SEC on November 14, 2016)
